NCT04414163 - A Study of IMC-001 in Subjects With Relapsed or Refractory Extranodal NK/T Cell Lymphoma, Nasal Type | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 27, 2020

Primary Completion Date

July 30, 2024

Study Completion Date

February 28, 2026

Conditions

Extranodal NK/T-cell Lymphoma, Nasal TypeExtranodal NK/T-cell Lymphoma

Interventions

DRUG

IMC-001

Single dose level for enrollment subject (IMC-001 20mg/kg every 2 weeks)

Trial Locations (5)

Chonnam National University Hwasun Hospital, Gwangju

Asan Medical Center, Seoul

Samsung Medical Center, Seoul

Seoul National University Hospital, Seoul

Ulsan University Hospital, Ulsan